The guidelines for the treatment of patients with lung cancer are based on a number of factors including disease type and patient considerations. The cancer treatment guidelines below offer a concise description of National Comprehensive Cancer Network (NCCN) guidelines for mesothelioma, non-small cell lung cancer, and small cell lung cancer.

The lung cancer treatment regimens include chemotherapy regimens for neoadjuvant and adjuvant therapy, sequential chemotherapy/radiotherapy, concurrent chemotherapy/radiotherapy followed by chemotherapy, and systemic therapy for advanced disease. The regimens also outline principles of maintenance therapy and subsequent therapy.

The mesothelioma treatment regimens include guidelines for first-line and second-line chemotherapies such as pemetrexed + carboplatin, gemcitabine + cisplatin, vinorelbine, pemetrexed + cisplatin + bevacizumab, and gemcitabine.

The lung cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. These regimens are only provided to supplement the latest treatment strategies.